Treating cognition with, aminocyclopropanecarboxylic derivatives

• US 5,428,069 A
• Filed: 01/11/1993
• Issued: 06/27/1995
• Est. Priority Date: 01/11/1993
• Status: Expired due to Fees

• Current Assignee: Philip Skolnick, The United States of America As Represented By The Secretary of Agriculture
• Original Assignee: United States Department Of Health And Human Services (Government of the United States of America)
• Inventors: Faiman, Claudia P., Viu, Eugenia, Trullas, Ramon, Skolnick, Phil
• Primary Examiner(s): Cintins, Marianne M.
• Assistant Examiner(s): CRIARES, THEODORE J
• Application Number:
  US08/003,225
• Time in Patent Office: 897 Days
• Field of Search: 514/531, 514/557
• US Class Current: 514/531
• CPC Class Codes: A61K 31/195 having an amino group
• CPC Class Codes: A61K 31/47 Quinolines; Isoquinolines
• CPC Class Codes: A61P 25/00 Drugs for disorders of the nervous system
• CPC Class Codes: A61P 25/08 Antiepileptics; Anticonvulsants
• CPC Class Codes: A61P 25/28 for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
• CPC Class Codes: A61P 43/00 Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Abstract

The use of a compound possessing functional antagonist properties at the NMDA receptor complex through a specific action at the associated strychnine-insensitive glycine site to improve cognition in normal humans and to treat cognitive deficits resulting from chronic neuronal degeneration, acute brain injury, hypoxia, or other neurological disorders is provided. The compounds possessing functional antagonist properties comprise 1-aminocyclopropanecarboxylic acid, and its pharmaceutically acceptable esters, salts, and acid addition salts or 7-chlorokynurenic acid, and its pharmaceutically acceptable esters, amides, salts, ethers, and acid addition salts.

Claims

1. A method to treat a cognitive deficit consequent to a neurological disorder resulting from or associated with chronic neuronal degeneration or an acute brain injury, comprising administering to a patient suffering from a cognitive deficit resulting from hypoxia, Parkinson disease, dementia, lathyrism, neurodegenerative diseases or head trauma a therapeutically-effective amount of at least one compound having the formula:

##STR5## wherein;

A is -CO₂ H or a pharmaceutically acceptable ester, amide, or salt thereof; and

X is -NR¹ R² or a pharmaceutically acceptable acid addition salt thereof, wherein R¹ and R² are selected independently from the group consisting of hydrogen and lower alkyl substituted optionally from the group consisting of halogen, hydroxyl, alkoxy, oxo, mercapto, aryl or amino,

to thereby improve or enhance the memory of said patient.

2. The method of claim 1, wherein said at least one compound is 1-aminocyclopropanecarboxylic acid.